Biogen Loses Patent Case Over Its Best-Selling Drug
Biogen's (NASDAQ: BIIB) Tecfidera is one of the world's best-selling multiple sclerosis drugs, and on Thursday, a judge in the Northern District of West Virginia ruled that a key patent on it is invalid. The decision means that Mylan (NASDAQ: MYL), the plaintiff in the suit, will be able to launch a generic version of the drug, which last year accounted for $4.4 billion of Biogen's $14.4 billion in revenue.
IMAGE SOURCE: GETTY IMAGES.
Tecfidera is a twice-daily oral drug prescribed to reduce the number and severity of MS relapses. Patent '514, which was just invalidated, would have protected it from generic competition until 2028.
Source Fool.com
